Compare Johnson & Johnson (JNJ) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs LTC Properties Inc — how do they compare? Johnson & Johnson trades at $259.5 (market cap $618.09B), while LTC Properties Inc trades at $42.51 (market cap $2.27B). The key difference: Johnson & Johnson is far larger — about 272.3× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.42%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and LTC Properties Inc for 89 Days on average.
| JNJ | LTC | |
|---|---|---|
Market Cap | $618.09B | $2.27B |
Volume | 6,050,983 | 574,171 |
Sector | Health | Real Estate |
52-Week High | $278.43 | $43.50 |
52-Week Low | $186.00 | $33.98 |
Typical Hold Time | 129 Days | 89 Days |
Enterprise Value | $646.37B | $3.01B |
Dividend Yield | 2.09% | 5.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
LTC Properties trades at $42.37, up 1.34% with a bullish technical signal. The REIT shows strong fundamentals with 2025 revenue of $262.85M and net income of $117.97M, delivering a 38.93% net margin. Recent acquisitions totaling $360M accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Analyst consensus sits at $49.67 with mixed ratings (7 Buy, 12 Hold, 3 Sell) amid strategic shifts.
Outlook remains positive due to demographic tailwinds in senior housing, though rising rates and execution risks on $730M asset sales pose challenges. Current valuation at P/E 15.02 appears reasonable for growth prospects, with technical support at $41-42 offering near-term stability. The stock presents a balanced opportunity for income and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
